Want to see AU:ACW full AI Analyst Report?
Top Page
Actinogen Medical
(Sydney:ACW)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$0.04
▲(10.00% Upside)
Action:Reiterated
Date:07/11/26
The score is held down primarily by weak financial performance, including declining revenue, ongoing losses, and negative operating/free cash flow. Technicals are a partial offset with price above major moving averages and moderately positive momentum, but stretched stochastic conditions limit confidence. Valuation is also a drag given the negative P/E (loss-making) and lack of dividend support.
Positive Factors
Lead Product Pipeline
Xanamem targets Alzheimer’s and major depressive disorder via 11β-HSD1 inhibition, addressing large, enduring therapeutic markets. A successful clinical program or licence would create durable upside through sizable addressable populations, long product lifecycles, and potential partnering or royalty revenue streams.
Negative Factors
Declining Revenue and Losses
A sharp revenue decline (-39.16%) combined with persistent negative net/EBIT/EBITDA margins indicates the company is not generating commercial income. This structural lack of revenue forces reliance on trial milestones and external funding, constraining the company’s ability to self-fund development and grow sustainably.
Read all positive and negative factors
Positive Factors
Negative Factors
Lead Product Pipeline
Xanamem targets Alzheimer’s and major depressive disorder via 11β-HSD1 inhibition, addressing large, enduring therapeutic markets. A successful clinical program or licence would create durable upside through sizable addressable populations, long product lifecycles, and potential partnering or royalty revenue streams.
Read all positive factors
Actinogen Medical (ACW) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$167.37M
Dividend YieldN/A
Average Volume (3M)6.03M
Price to Earnings (P/E)―
Beta (1Y)-0.34
Revenue GrowthN/A
EPS Growth-70.59%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,719,366,000
10 Day Avg. Volume4,755,726
30 Day Avg. Volume6,028,147
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.74
Price to Sales (P/S)12.48
P/FCF Ratio-9.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.08Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$10.10M
Actinogen Medical Business Overview & Revenue Model
Company Description
Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HS...
How the Company Makes Money
Actinogen Medical is a clinical-stage biotechnology company and, based on publicly available information, it does not appear to generate material recurring revenue from product sales. Its primary source of funding is typically capital raising (e.g...
Actinogen Medical Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.49M | 5.49M | 9.93M | 4.89M | 3.64M | 1.98M |
| Gross Profit | 5.28M | 5.49M | 9.93M | 4.48M | 3.24M | 1.60M |
| EBITDA | -19.88M | -15.01M | -12.84M | -15.22M | -12.72M | -5.35M |
| Net Income | -17.91M | -14.73M | -13.04M | -10.75M | -9.50M | -3.92M |
Balance Sheet | ||||||
| Total Assets | 10.60M | 24.48M | 21.31M | 15.21M | 23.31M | 18.38M |
| Cash, Cash Equivalents and Short-Term Investments | 6.53M | 16.50M | 9.45M | 8.46M | 16.37M | 13.42M |
| Total Debt | 366.31K | 3.26M | 319.07K | 86.93K | 165.27K | 236.44K |
| Total Liabilities | 2.23M | 6.15M | 1.62M | 1.80M | 1.57M | 920.32K |
| Stockholders Equity | 8.37M | 18.34M | 19.70M | 13.41M | 21.74M | 17.46M |
Cash Flow | ||||||
| Free Cash Flow | -16.45M | -7.59M | -16.96M | -8.73M | -9.52M | -1.73M |
| Operating Cash Flow | -16.41M | -7.56M | -16.95M | -8.70M | -9.52M | -1.72M |
| Investing Cash Flow | -38.37K | -38.02K | -8.16K | -36.60K | -2.94K | -6.19K |
| Financing Cash Flow | 116.65K | 14.65M | 17.95M | 824.62K | 12.42M | 10.11M |
Actinogen Medical Technical Analysis
Positive
0.04
Price Trends
0.04
Positive
0.04
Positive
0.04
Positive
Market Momentum
<0.01
Negative
67.95
Neutral
86.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACW, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 67.95 is Neutral, neither overbought nor oversold. The STOCH value of 86.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ACW.
Actinogen Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$2.92B | 96.29 | 9.20% | ― | -69.69% | -78.38% | |
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$167.37M | -7.93 | -134.14% | ― | ― | -70.59% | |
48 Neutral | AU$116.62M | -7.26 | -30.19% | ― | ― | 62.66% | |
45 Neutral | AU$60.41M | -16.09 | -68.12% | ― | ― | 57.89% | |
42 Neutral | AU$22.02M | -3.82 | -19.10% | ― | ― | -285.37% |
* Healthcare Sector Average
AU:ACW
Actinogen Medical
0.05
0.02
88.00%
AU:ENP
Tryptamine Therapeutics
0.04
<0.01
5.88%
AU:NEU
Neuren Pharmaceuticals Limited
23.64
5.76
32.21%
AU:ATH
Alterity Therapeutics
0.54
-0.16
-22.86%
AU:ZLD
Zelira Therapeutics
0.50
0.09
21.95%
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.06
-0.14
-71.00%
Actinogen Medical Corporate Events
Actinogen Medical Seeks ASX Quotation for New Share Issue
Jul 28, 2026
Actinogen Medical Limited has applied to the Australian Securities Exchange for quotation of 340,002 new ordinary fully paid shares under the code ACW. The securities, issued on 28 July 2026, arise from the exercise of options or conversion of oth...
Actinogen Medical Announces Employee Share Scheme Buy-Back
Jul 13, 2026
Actinogen Medical Ltd., an ASX-listed biotechnology company trading under the ticker ACW, has disclosed a buy-back involving its ordinary fully paid shares. The move is tied to its employee share scheme, underscoring the firm’s reliance on e...
Actinogen highlights biomarker-driven progress in pivotal Xanamem Alzheimer’s trial
Jul 12, 2026
Actinogen Medical has showcased new data from its fully enrolled XanaMIA phase 2b/3 trial of Xanamem in mild to moderate Alzheimer’s disease at the Alzheimer’s Association International Conference in London. The company highlighted tha...
Actinogen boosts director equity with new Employee Share Plan issue
Jun 24, 2026
Actinogen Medical has disclosed a change in director Dr Geoffrey Brooke’s interest following the issue of 9 million fully paid ordinary shares to him under the company’s Employee Share Plan. The new allocation, approved by shareholders...
Actinogen Medical Seeks ASX Quotation for 56 Million New Shares
Jun 24, 2026
Actinogen Medical has applied to the ASX for quotation of 56,000,000 new ordinary fully paid shares under its code ACW, with an issue date of June 24, 2026. The move expands the company’s quoted share capital and may enhance its access to eq...
Actinogen shareholders back all resolutions as Xanamem trials advance
Jun 23, 2026
Actinogen Medical reported that all five resolutions put to shareholders at its general meeting were passed as ordinary resolutions by poll. The meeting outcomes reinforce board and investor backing as the company advances its late-stage XanaMIA P...
Actinogen Medical Seeks ASX Quotation for New Share Issue
Jun 18, 2026
Actinogen Medical Limited has applied for quotation on the ASX of 3,147,358 ordinary fully paid shares, to be issued on 18 June 2026 under the ticker ACW. The new securities arise from the exercise or conversion of existing options or other conver...
Actinogen clears third safety review in pivotal Alzheimer’s trial
Jun 17, 2026
Actinogen Medical said an independent Data Monitoring Committee has, for the third time, recommended that its 247-patient XanaMIA phase 2b/3 pivotal trial in mild to moderate Alzheimer’s disease continue without amendment, following a review...
Actinogen wins aligned EMA and FDA backing for Xanamem Alzheimer’s path
May 28, 2026
Actinogen Medical has secured positive scientific advice from the European Medicines Agency for its Alzheimer’s program, aligning closely with prior guidance from the U.S. FDA and clarifying the path to potential marketing approvals in both ...
Actinogen Medical Seeks ASX Quotation for 66.7 Million New Shares
May 21, 2026
Actinogen Medical has applied to the ASX for quotation of 66.7 million new ordinary fully paid shares, expanding its listed securities under the code ACW. The issuance of these shares, some of which relate to an employee incentive scheme, increase...
Actinogen convenes June shareholder meeting as Xanamem trials advance
May 21, 2026
Actinogen Medical has called a general meeting of shareholders to be held in person in Sydney on 23 June 2026, with meeting materials and proxy voting available online through its investor and registry platforms. The company is also urging investo...
Actinogen CEO Exercises Options as Key Alzheimer’s Trial Milestone Nears
May 13, 2026
Actinogen Medical has highlighted that two tranches of unlisted options, ACWOPT10 and ACWOPT11, each exercisable at $0.0375, are due to expire in September 2026, and reminded holders to allow sufficient time for exercise and payment processing. Th...
Actinogen CEO Steven Gourlay Boosts Shareholding Through Option Exercise
May 13, 2026
Actinogen Medical has disclosed a change in director Dr Steven Gourlay’s interests following the exercise of unlisted options into fully paid ordinary shares. Gourlay converted a total of 2,442,647 unlisted options, increasing both his direc...
Actinogen Medical Seeks ASX Quotation for 2.44m New Shares
May 13, 2026
Actinogen Medical Limited, an Australian biotechnology company listed on the ASX under ticker ACW, has issued additional fully paid ordinary shares as part of its ongoing capital management and corporate development activities.The company has appl...
Actinogen Seeks ASX Quotation for 60,000 New Shares
May 11, 2026
Actinogen Medical Limited has applied to the ASX for quotation of 60,000 new ordinary fully paid shares, issued on 10 May 2026 under its ticker ACW. The additional securities arise from the exercise or conversion of existing options or other conve...
Actinogen cancels 2.8m shares under employee scheme buy-back
May 3, 2026
Actinogen Medical has notified the market of the cessation of 2,833,335 ordinary fully paid shares, following their cancellation under an employee share scheme buy-back. The adjustment to issued capital reflects ongoing management of its employee ...
Actinogen extends cash runway as pivotal Alzheimer’s trial advances
Apr 29, 2026
Actinogen Medical reported progress on its pivotal XanaMIA phase 2b/3 Alzheimer’s trial, with an independent Data Monitoring Committee recommending the study continue unchanged after a positive interim analysis of safety and futility. The 24...
Actinogen extends cash runway as pivotal Alzheimer’s trial advances
Apr 29, 2026
Actinogen Medical reported steady progress in its pivotal XanaMIA phase 2b/3 Alzheimer’s disease trial, with an independent data monitoring committee recommending the study continue unchanged after a positive interim analysis, and topline re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.